Neuland Laboratories Q4 FY26 Results: PAT Rs 212.67 Crore Up 424 Percent YoY Revenue Rs 788.71 Crore
- May 13, 2026
- Posted by: Kashish Aggarwal
- Category: News
Neuland Laboratories Q4 FY26 results were announced on 12 May 2026, with the company reporting a consolidated net profit of Rs 212.67 crore for the quarter ended March 31, 2026, a 424 percent year-on-year increase from Rs 40.57 crore in Q4 FY25. Revenue from operations rose 76 percent year-on-year to Rs 788.71 crore. The Neuland Laboratories Q4 FY26 performance will be assessed by investors against the broader macro backdrop of India’s economic recovery, sectoral dynamics in Specialty Pharmaceuticals, and management commentary on the FY27 outlook.
Click Here – Get Free Investment Predictions
Neuland Laboratories reported a sharp sequential surge in Q4 FY26, with total income rising to Rs 788.71 crore from Rs 447.76 crore in Q3 FY26, driven by strong API demand and ramp-up in CDMO contracts.
Neuland Laboratories Q4 FY26 Key Financial Highlights
The following table summarises key Neuland Laboratories Q4 FY26 financial highlights as reported on 12 May 2026.
| Parameter | Q4 FY26 | Reference |
|---|---|---|
| Net Profit (PAT) | Rs 212.67 crore | Rs 40.57 crore (Q4 FY25) |
| PAT Change YoY | +424% | Reference period |
| Revenue from Operations | Rs 788.71 crore | Rs 447.76 crore (Q4 FY25) |
| Revenue Change YoY | +76% | Reference period |
| CMP (NSE) | Rs 17,000 | As of 12 May 2026 |
| NSE Ticker | NEULANDLAB | Sector: Specialty Pharmaceuticals |
Screen the best stocks on the Univest Screener.
Investors tracking KPR Mill Q4 FY26 results can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.
Neuland Laboratories Q4 FY26 Profit Analysis
Neuland Laboratories Q4 FY26 net profit of Rs 212.67 crore represents a 424 percent year-on-year increase in Specialty Pharmaceuticals. The growth was supported by strong operational execution, volume expansion and favourable cost dynamics. Investors will closely monitor management commentary on margin trajectory and FY27 guidance from these Neuland Laboratories Q4 FY26 results.
The Q4 FY26 performance places Neuland Laboratories among the outperformers in the Specialty Pharmaceuticals sector for the March 2026 quarter. The company operates in Specialty Pharmaceuticals, a sector that is closely watched for demand trends, margin recovery, and volume growth in the context of India’s overall economic momentum in FY27.
Investors tracking KPR Mill Q4 FY26 results can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.
Revenue and Operating Performance in Neuland Laboratories Q4 FY26
Revenue from operations in Neuland Laboratories Q4 FY26 grew 76 percent year-on-year to Rs 788.71 crore, reflecting robust demand and improved pricing power. The Neuland Laboratories Q4 FY26 operating performance will be evaluated against the context of broader industry trends, raw material costs, and demand conditions in the company’s key markets.
Management commentary on volume growth, pricing power, margin trajectory, and order book position will be key inputs for analysts revising their FY27 estimates following these Neuland Laboratories Q4 FY26 results.
Investors tracking KPR Mill Q4 FY26 results can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.
Neuland Laboratories Q4 FY26 Stock Price and Market Position
Neuland Laboratories is listed on the NSE under the ticker NEULANDLAB and operates in the Specialty Pharmaceuticals sector. Following the Neuland Laboratories Q4 FY26 results announcement on 12 May 2026, the stock will be assessed by the market based on the quarterly profitability trajectory, management commentary on FY27 outlook, and dividend decision. The stock was trading at Rs 17,000 on the NSE as of 12 May 2026. Investors should track live price movements and analyst rating changes on the Univest Screener.
Investors tracking KPR Mill Q4 FY26 results can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.
Neuland Laboratories FY27 Outlook
Post Neuland Laboratories Q4 FY26 results, the key areas of investor focus for FY27 include management’s guidance on revenue growth, operating margin trajectory, capital expenditure plans, and demand visibility in the Specialty Pharmaceuticals sector. The strong Q4 FY26 performance sets a positive base for FY27 earnings delivery and potential re-rating of the stock. The broader macroeconomic backdrop of India’s continued growth momentum, RBI rate cuts, and sectoral policy tailwinds will also shape the FY27 earnings outlook for Neuland Laboratories.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on Neuland Laboratories Q4 FY26 Results
What is Neuland Laboratories Q4 FY26 net profit?
Ans. Neuland Laboratories Q4 FY26 consolidated net profit is Rs 212.67 crore, a 424 percent year-on-year increase from Rs 40.57 crore in Q4 FY25.
When did Neuland Laboratories announce Q4 FY26 results?
Ans. Neuland Laboratories announced Q4 FY26 results on 12 May 2026, through a board meeting held on the same date, with filings submitted to BSE and NSE thereafter.
What was Neuland Laboratories revenue in Q4 FY26?
Ans.
Ans. Neuland Laboratories Q4 FY26 revenue from operations was Rs 788.71 crore, +76% year-on-year.
What is the FY27 outlook for Neuland Laboratories?
Ans. Post Q4 FY26 results, investors will closely monitor management guidance on revenue growth, margin trajectory, and capital allocation in the Specialty Pharmaceuticals sector for FY27.
Where can I track Neuland Laboratories Q4 FY26 live price?
Ans. Track Neuland Laboratories live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research.
The KPR Mill Q4 FY26 results performance reflects the company’s position in its sector.
The KPR Mill Q4 FY26 results performance reflects the company’s position in its sector.
The KPR Mill Q4 FY26 results performance reflects the company’s position in its sector.
The KPR Mill Q4 FY26 results performance reflects the company’s position in its sector.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.
